Brady Camplin

Brady Camplin is a molecular biologist with a Master of Science in Biomedical Engineering from Boston University, focusing on synthetic biology and gene therapy. They have several years of experience at Ultragenyx Pharmaceutical Inc. as a Senior Research Associate in Vector Engineering, where they led various research projects related to AAV gene therapy. Currently, Brady serves as a Senior Scientist at Eli Lilly and Company, conducting quality assays for AAV gene therapies. Additionally, they have engaged in fieldwork as a wildlife biologist and have participated in environmental conservation efforts.